 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Clinical Pharmacist, Falls Community Health; Assistant Professor of Pharmacy Practice, College of Pharmacy, South Dakota State University, Sioux Falls, SD
Clinical Pharmacist, East Des Moines Family Care Center; Assistant Professor (Clinical), College of Pharmacy, University of Iowa, Des Moines, IA
Clinical Pharmacist, Sanford USD Medical Center, Sioux Falls, SD
Pediatric Resident Physician, Mayo Clinic, Rochester, MN
Reprints: Dr. Karly Hegge, College of Pharmacy, South Dakota State University, University Center North, 4801 N. Career Ave., Sioux Falls, SD 57106, fax 605/367-8423, karly.hegge{at}sdstate.edu
OBJECTIVE: To summarize the role of pharmacotherapy in the management of phenylketonuria (PKU) and to review the pharmacology, pharmacokinetics, pharmacodynamics, efficacy data, and safety profile of sapropterin for this indication.
DATA SOURCES: A literature search was conducted using MEDLINE (1966-May 2009), International Pharmaceutical Abstracts (1970-May 2009), and Cochrane database (2008) for the following key words: sapropterin, tetrahydrobiopterin, phenylketonurias, and phenylalanine.
STUDY SELECTION AND DATA EXTRACTION: English-language studies involving humans examining the role of tetrahydrobiopterin (BH4) in the management of PKU were reviewed to evaluate the pharmacology, pharmacokinetics, pharmacodynamics, efficacy data, and safety profile for sapropterin. All Phase 2 and 3 randomized controlled trials assessing the safety and efficacy of sapropterin were included in this literature evaluation.
DATA SYNTHESIS: Sapropterin represents the only Food and Drug Administration-approved medication for BH4-responsive PKU, marking an important advance in the treatment of this condition. Among individuals with hyperphenylalaninemia and some residual phenylalanine hydroxylase function, sapropterin can enhance activity of this enzyme to decrease serum phenylalanine concentrations. Sapropterin has been compared with placebo in one Phase 2 and one Phase 3 clinical trial, demonstrating significantly better response rates. Based on available studies, this agent appears to be safe and well tolerated, with adverse event rates similar to those of placebo. However, additional studies are warranted to assess the long-term safety and efficacy of sapropterin therapy.
CONCLUSIONS: Sapropterin offers a promising therapeutic option for select individuals with BH4-responsive PKU, although long-term data are limited evaluating its safety and efficacy in traditional clinical practice settings. When considering sapropterin therapy, clinicians must consider factors such as cost and patient adherence to drug therapy and/or diet.
Key Words: 5,6,7,8-tetrahydrobiopterin, BH4, 6R-BH4, sapropterin, Kuvan, phenylketonurias, phenylalanine
Published Online, August 4, 2009. www.theannals.com, DOI 10.1345/aph.1M050
THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE
UNIVERSAL PROGRAM NUMBER: 407-000-09-015-H01-P
 |
 |
 |
 |
 |
 |
 |
